ArticleVirchows Archiv : an international journal of pathology2010
Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma.
Article in Virchows Archiv : an international journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis.Scientific reports · 2016Pooled it
- Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.Cancer research communications · 2026Trial
- TROP2 expression as a prognostic predictor for osimertinib in patients withTranslational lung cancer research · 2026Article
- Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy.Scientific reports · 2025Article
- Trop-2 expression in non-small cell lung cancer.PloS one · 2025Article
- Epithelial Cell Adhesion Molecule (EpCAM) Expression in Human Tumors: A Comparison with Pan-Cytokeratin and TROP2 in 14,832 Tumors.Diagnostics (Basel, Switzerland) · 2024Article
- Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma.Human pathology · 2023Article
- Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.Journal of cancer research and clinical oncology · 2022Article
- Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.Frontiers in oncology · 2022Article
- Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.Molecular cancer therapeutics · 2021Article
- Trop2: Jack of All Trades, Master of None.Cancers · 2020Review
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.Oncotarget · 2018Review
- The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms.Applied immunohistochemistry & molecular morphology : AIMM · 2017Article
- Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes.Oncotarget · 2017Article
- Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.Cancer management and research · 2017Article
- MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer.Journal of experimental & clinical cancer research : CR · 2015Article
- siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells.Experimental and therapeutic medicine · 2015Article
- Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.Genes & cancer · 2015Review
- Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer.Molecular and cellular biochemistry · 2014Article
- Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma.Oncology letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The GA733 gene family is composed of GA733-1 (TROP2) and GA733-2 (Ep-CAM), whose expression has been examined in various carcinomas and reported to be significantly associated with prognosis. The aim of this study was to investigate the expression of GA733 gene family members and to compare their prognostic significance in pulmonary adenocarcinoma. One hundred thirty paraffin-embedded specimens of small-sized pulmonary adenocarcinoma, less than 2 cm in diameter, were categorized using the classification of small-sized pulmonary adenocarcinoma devised by Noguchi et al. (Cancer 75:2844-2852, 1995) and examined immunohistochemically using a murine monoclonal antibody against Ep-CAM and a goat polyclonal antibody against TROP2. The patient survival rate was calculated using the Kaplan-Meier method. Ep-CAM and TROP2 were similarly expressed in many small-sized pulmonary adenocarcinomas. The expression of Ep-CAM was significantly related to a favorable outcome (p = 0.0185), whereas TROP2 tended to be expressed in cases with an unfavorable outcome (p = 0.0564), and was significantly associated with an unfavorable outcome in nonlepidic-type adenocarcinomas (p = 0.0125). Multivariate analysis showed that TROP2 overexpression and lymph node metastasis were independent prognostic markers. Although the two GA733 proteins share structural similarity, they appear to have opposite biological significances in small-sized adenocarcinomas. As the expression of TROP2 was detected in more poorly differentiated tumors, the protein may have oncogenic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.